Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biology and potential strategies for the treatment of GM2 gangliosidoses.

Molecular medicine today - 1 Apr 1998

Chavany C, Jendoubi M

Abstract excerpt

The GM2 gangliosidoses are a group of heritable neurodegenerative disorders caused by excessive accumulation of the ganglioside GM2 owing to deficiency in beta-hexosaminidase activity. Tay-Sachs and Sandhoff diseases have similar clinical phenotypes resulting from a deficiency in human hexosaminidase alpha and beta subunits, respectively. The lack of treatment for GM2 gangliosidoses stimulated interest in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Bone Marrow Transplantation
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Models, Animal

Share to Genetic Therapy

Share to Genetic Vectors

Share to Infant

Source

Identifiers

PMID: 9572057
DOI: 10.1016/s1357-4310(98)01227-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biology and potential strategies for the treatment of GM2 gangliosidoses.PMID 9572057Read ↗

Genetics and Therapies for GM2 Gangliosidosis.Semantic proximity Read ↗

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects and Current TherapiesSemantic proximity Read ↗

GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.Semantic proximity Read ↗

Gene therapy approaches for GM1 gangliosidosis: Focus on animal and cellular studies.Semantic proximity Read ↗

Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosisSemantic proximity Read ↗

[Recent advances in molecular genetics of GM2 gangliosidosis].Semantic proximity Read ↗

[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].Semantic proximity Read ↗

The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.Semantic proximity Read ↗

Gene Therapy of Sphingolipid Metabolic DisordersSemantic proximity Read ↗

Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.Semantic proximity Read ↗

Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosisSemantic proximity Read ↗

Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.